03/04/2024 – AB Science today announces that Health Canada has granted eligibility for reconsideration request for masitinib in amyotrophic lateral sclerosis (ALS) Download PDF Post navigationPreviousPrevious post:New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseNextNext post:AB Science announces a slight delay in the publication of its 2023 annual financial reportRelated PostsAnnual financial results as of 31 December, 2023May 15, 2024AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036May 13, 2024A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patientsMay 7, 2024The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB ScienceMay 2, 2024AB Science announces a slight delay in the publication of its 2023 annual financial reportApril 30, 2024New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseMarch 13, 2024
AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036May 13, 2024
A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patientsMay 7, 2024
The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB ScienceMay 2, 2024
AB Science announces a slight delay in the publication of its 2023 annual financial reportApril 30, 2024
New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseMarch 13, 2024